We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...

Stocks that are trending today. Stéphane Bancel, CEO of Moderna , said: "We remain focused on our strategy to build a large ...

On January 12, 2026, Moderna reported that it expected unaudited 2025 revenue of about $1.9 billion—slightly above prior guidance—alongside improved projected 2025 GAAP operating expenses of $5.0–$5.2 ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Moderna reiterated its plan to deliver up to 10% revenue growth in 2026 while further reducing operating expenses. The ...

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...